Hyaluronic Acid
| Evidence Level: L3 | Predicted Indications: 9 |
Table of Contents
Hyaluronic Acid: Sjogren syndrome
One-Sentence Summary
Hyaluronic acid is a lubricating, hydrating glycosaminoglycan that is marketed in India in injectable, topical, serum and oral forms. The TxGNN model predicts it may be useful as supportive, symptomatic care in Sjogren syndrome, with a score of 0.9974. Support comes from 1 loosely related clinical trial and about 20 publications, mostly small clinical or observational studies of hyaluronic acid-containing preparations in Sjogren patients. No randomized trial specific to Sjogren syndrome was found.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Sjogren syndrome |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on what is known, hyaluronic acid is a water-binding, viscoelastic polymer that lubricates and protects mucosal and ocular surfaces.
Sjogren syndrome is an autoimmune destruction of the lacrimal and salivary glands, which causes ocular dryness and dry mouth. A lubricant and surface protectant can plausibly relieve these symptoms and improve tear film stability.
Hyaluronic acid does not modify the underlying autoimmune process. Any benefit would be supportive and symptomatic, not disease-modifying.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02257957 | Phase 3 | Completed | 30 | Platelet-rich plasma injection for severe ocular surface dryness. Hyaluronic acid is not the investigational agent, and the link to Sjogren syndrome is indirect. |
No registered trial tests hyaluronic acid directly in Sjogren syndrome.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28557655 | 2017 | Clinical study | J Ocul Pharmacol Ther | Compared tear film stability after hyaluronic acid versus cross-linked hyaluronic acid eye drops in Sjogren patients with ocular dryness |
| 28375792 | 2017 | Clinical trial | J Ocul Pharmacol Ther | Evaluated safety and efficacy of 0.3% cortisol phosphate eye drops in a hyaluronic acid vehicle in Sjogren-related ocular dryness |
| 35370264 | 2022 | Formulation study | Biol Pharm Bull | Hyaluronate sheets containing pilocarpine were developed as a topical treatment for xerostomia, including in Sjogren syndrome, to reduce systemic side effects |
| 9797560 | 1998 | Observational | Ann Rheum Dis | Measured salivary and serum hyaluronic acid concentrations in primary Sjogren syndrome |
| 15110955 | 2004 | Review | Rev Med Interne | Reviewed the treatments used for xerophthalmia and keratoconjunctivitis sicca in Sjogren syndrome |
| 30830076 | 2019 | Clinical study | Vestn Oftalmol | Evaluated the antioxidative effect of artificial tears in severe keratoconjunctivitis sicca in Sjogren patients |
| 29296554 | 2017 | Clinical study | Taiwan J Ophthalmol | Examined serum components and efficacy of autologous serum eye drops in active and inactive Sjogren syndrome |
| 23890196 | 2014 | Clinical and experimental study | Acta Ophthalmol | Assessed sodium hyaluronate as a vehicle for diluting autologous serum eye drops |
| 10364906 | 1999 | Clinical study | Ann Rheum Dis | Hydroxychloroquine study in primary Sjogren syndrome; hyaluronic acid was measured only as a biomarker |
| 40346044 | 2025 | Preclinical | Int J Oral Sci | Hydrogel platform for expanding functional salivary acinar cell spheroids, relevant to xerostomia in Sjogren syndrome |
India Market Information
Hyaluronic acid is marketed in India, and all licences in the data compiled for this report are valid. The list below shows five main authorizations and may be partial.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 103750 | Hyalgan Injection | Prefilled syringe of 2 ml, injection | Not specified |
| 234935 | Viscosafe 14mg Injection | Vial of 1 ml, injection | Not specified |
| 247678 | Zyonate 14mg Injection | Vial, injection | Not specified |
| 104311 | Hyaluron 200mg Tablet | Strip of 10 tablets | Not specified |
| 87764 | Fain 0.5% Gel | Tube of 10 gm, gel | Not specified |
Safety Considerations
- Drug Interactions (moderate level): topical cetylpyridinium and topical benzalkonium.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Small clinical studies of hyaluronic acid-based eye drops and sheets in Sjogren patients support a symptomatic role, so the evidence level is L3. No randomized trial specific to Sjogren syndrome exists, and hyaluronic acid does not address the autoimmune cause. The use should be framed as supportive care.
To proceed, the following is needed:
- A randomized, controlled trial of hyaluronic acid alone in Sjogren patients, with ocular and oral symptom endpoints
- Detailed mechanism-of-action data
- Package insert warnings and contraindications for the relevant formulations
- Confirmation of which formulation and route (ocular, oral or other) suit the target symptoms, as the licensed forms in India are mainly injectable and topical
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.